Why the study?
Does mexiletine preferentially suppress conduction in the reentrant circuit of ventricular tachycardia in patients with underlying heart disease?
Does mexiletine preferentially suppress conduction in the reentrant circuit of ventricular tachycardia in patients with underlying heart disease?
Mexiletine appears to selectively suppress conduction in abnormal myocardium involved in the slow conduction pathway of ventricular tachycardia reentrant circuits.
May selectively slow conduction in VT reentry circuits; leaves open clinical utility pending controlled studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Abe et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: